Relapsed/Refractory Acute Myeloid Leukemia (R/R AML)

Oncology
1
Pipeline Programs
1
Companies
1
Clinical Trials
1 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
1
0
0
0
0
0
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Cell Therapy
1100%

Competitive Landscape

1 companies ranked by most advanced pipeline stage

Hemogenyx Pharmaceuticals
1 program
1
Anti-FLT3 CAR-T cellsPhase 1Cell Therapy1 trial
Active Trials
NCT06786533RecruitingEst. Jan 2027

Trial Timeline

Clinical trial activity over time

2025
2026
2027
Hemogenyx PharmaceuticalsAnti-FLT3 CAR-T cells

Clinical Trials (1)

Clinical Study of Anti-FLT3 CAR-T Cells for the Treatment of Relapsed/Refractory AML

Start: Jan 2025Est. completion: Jan 2027
Phase 1Recruiting

Related Jobs in Oncology

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

1 actively recruiting trials
1 companies competing in this space